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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.009Endothelial dysfunction, including endothelial hyporesponsiveness to prototypical angiogenic growth
factors and eNOS agonists, underlies vascular pathology in many dysmetabolic states. We investigated
effects of a saturated free fatty acid, palmitic acid (PA), on endothelial cell responses to VEGF. PA-
pretreated endothelial cells had markedly diminished Akt, eNOS, and ERK activation responses to VEGF,
despite normal VEGFR2 phosphorylation. PA inhibited VEGF-induced angiogenic cord formation in
Matrigel, and PA-treated endothelial cells accumulated early species (C16) ceramide. The serine pal-
mitoyltransferase inhibitor myriocin reversed these defects. Protein phosphatase 2A (PP2A) became
more eNOS-associated in PA-treated cells; the PP2A inhibitor okadaic acid reversed PA-induced
signaling defects. Mice fed a diet high in saturated fat for 2 to 3 weeks had impaired i) aortic Akt and
eNOS phosphorylation to infused VEGF, ii) ear angiogenic responses to intradermal adenoviral-VEGF
injection, and iii) vascular ﬂow recovery to hindlimb ischemia as indicated by laser Doppler and aVb3
SPECT imaging. High-fat feeding did not impair VEGF-induced signaling or angiogenic responses in mice
with reduced serine palmitoyltransferase expression. Thus, de novo ceramide synthesis is required for
these detrimental PA effects. The ﬁndings demonstrate an endothelial VEGF resistance mechanism
conferred by PA, which comprises ceramide-induced, PP2A-mediated dephosphorylation of critical
activation sites on enzymes central to vascular homeostasis and angiogenesis. This study deﬁnes po-
tential molecular targets for preservation of endothelial function in metabolic syndrome. (Am J Pathol
2014, 184: 1562e1576; http://dx.doi.org/10.1016/j.ajpath.2014.01.009)SupportedbyNIHgrantsR01-HL061782 (J.R.B.),T32-HL007950 (V.C.M.),
R01-DK400936 (J.S.), and the Raymond and Beverly Sackler Foundation.
Disclosures: GE Healthcare provided the SPECT imaging agent.
Current address ofV.C.M., JohnsHopkinsMedicine, Baltimore,MD, and the
NationalHeart, Lung andBlood Institute, NIH,Bethesda,MD; ofE.J., School of
Medicine, American University of Antigua, Antigua.Endothelial dysfunction is the inability of the endothelium to
promote vasodilation in a stimulus-dependent fashion, primar-
ily as a consequence of impaired nitric oxide (NO) production.
Individuals with risk factors for vascular disease, including
metabolic syndrome and dysplipidemia,1 exhibit varying
degrees of endothelial dysfunction, which is an early feature of
vascular pathology with prognostic signiﬁcance.2 Elevation of
circulating free fatty acids (FFAs), experimentally or as seen in
obese insulin-resistant individuals and in type 2 diabetes, results
in 40% to 50% lower endothelium-dependent vasodilation.3,4
The elevation of circulating FFA in obesity, metabolic syn-
drome, and type 2 diabetes is associated with impaired
endothelium-dependent vasodilation, suggesting a link betweenstigative Pathology.
.FFA and endothelial dysfunction. We investigated such a link
by assessing the effect of FFA on NO-producing growth factor
signaling in the endothelium.
Similar to hyperinsulinemia in insulin resistance, elevated
systemic VEGF levels have been detected in individuals
with visceral obesity, type 2 diabetes, and atherosclerosis.5,6
VEGF levels are also elevated in chronically ischemic
Ceramide and Endothelial VEGF Resistancecoronary and peripheral artery disease states,6 as well as in
essential hypertension.7 In the present study, we evaluated
the effects of palmitic acid (PA) on endothelial signaling
responses to VEGF. PA profoundly impaired VEGF-
dependent eNOS activation and angiogenic responses
in vitro and in two independent in vivo murine models. The
effects of PA were dependent on de novo synthesis of cer-
amide, which increased association of protein phosphatase
2A (PP2A) with eNOS. Here, we discuss this VEGF resis-
tance as a possible central feature of the widespread vascular
pathology seen in numerous dysmetabolic states.
Materials and Methods
Reagents and Cells
Recombinant human VEGF-A165 was obtained from the Bio-
logical Resource Branch of the National Cancer Institute
(Frederick, MD). Sodium palmitate, C2 ceramide, myriocin,
okadaic acid (OkA), and bradykininwere obtained fromSigma-
Aldrich (St. Louis, MO). Antibodies to bovine eNOS and
p-eNOSwere from Life Technologies (Zymed brand; Carlsbad,
CA), antibodies to mouse eNOS were from BD Biosciences
(San Jose, CA), and antibodies to ERK1/2, p-ERK1/2, Akt,
p-Akt, and VEGFR2 were from Cell Signaling Technology
(Danvers, MA). Antibody to PP2A was from EMD Millipore
(Billerica, MA). Primary bovine aortic endothelial cells
(BAECs) were purchased from Lonza (Walkersville, MD) and
cultured in Dulbecco’s modiﬁed Eagle’s medium (Life Tech-
nologies) supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Flowery Branch, GA), 100 U/mL penicillin, 100
mg/mL streptomycin, and 2 mmol/L L-glutamine (Life Tech-
nologies) and were used up to passage 8. Human umbilical vein
endothelial cells (HUVECs) from the Yale Vascular Biology
Cell Culture Core Facility were cultured in medium 199 sup-
plemented with 20% fetal bovine serum, 100 U/mL penicillin,
100 mg/mL streptomycin, and EC growth supplement (BD
Biosciences) and were used up to passage 6. Fatty acids were
conjugated to bovine serum albumin before use by dissolving in
50% ethanolePBS. The solubilized fatty acid solution was
gently added dropwise into 1% essentially fatty acidefree
bovine serum albumin (BSA) solution at 45C. Conjugation of
the FFAs toBSA (molar ratio 2:1)was allowed to continue for at
least 1 hour at 37C. Vehicle control for fatty acids constituted
equivalent amounts of ethanol and BSA without the fatty acids,
and with ﬁnal ethanol concentrations never exceeding 0.1% (v/
v). Similarly, dimethyl sulfoxide at or below 0.1% (v/v) was
used as vehicle control for some inhibitors. Cell culture exper-
iments were routinely performed after 16 to 24 hours of serum
starvation of the cells in serum-free culture medium containing
0.1% essentially fatty acidefree BSA, unless otherwise noted.
Animal Models of High-Fat Feeding
All studies with animals were conducted according to a protocol
approved by the Yale University Institutional Animal Care andThe American Journal of Pathology - ajp.amjpathol.orgUse Committee. C57BL/6J and AKR/J mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). Mice hetero-
zygous for the serine palmitoyltransferase, long chain base
subunit 2 gene (Sptlc2/þmice) were backcrossed to C57BL/6J
mice for at least six generations and were maintained under
speciﬁc pathogenefree conditions. These mice express reduced
levels of serine palmitoyl-coenzyme A (CoA) transferase, a
rate-limiting enzyme in sphingolipid biosynthesis.8 Wild-type
littermates (Sptlc2þ/þ) were used as controls for Sptlc2/þ
mice. To elevate plasma FFA levels, 9- to 12-week-old mice
were fed ad libitum a 60% fat-based calorie diet (D12492;
Research Diets, New Brunswick, NJ) for 17 to 18 days (2.5
weeks). The FFA content of the high-fat diet was as follows (in
g/4057 kcal): myristic acid, 2.2; myristoleic acid, 1.2; PA, 58.7;
palmitoleic acid, 9.3; stearic acid, 33.5; oleic acid, 106.8;
linoleic acid, 34.4; linolenic acid, 4.4; and arachidonic acid, 4.2.
Control animals were maintained on normal mouse chow.
Plasma FFA levels were measured by an acyl-CoA oxidase-
based colorimetric assay [NEFA-HR(2); Wako Diagnostics,
Richmond, VA] as described previously.9
VEGF-Induced Aortic Kinase Activation in Vivo
Recombinant human VEGF-A165 or saline control was
infused via a left jugular vein catheter into anesthetized mice
fed normal chow (control) or a high-fat diet. After 5 mi-
nutes, animals were perfused with phosphatase inhibitors [1
mmol/L sodium orthovanadate (Na3VO4), 20 mmol/L NaF,
and 1 mmol/L sodium pyrophosphate (Na4P2O7)], after
which the mice were sacriﬁced and aortas were harvested
and immediately ﬂash frozen. Aortic tissue was then ho-
mogenized in lysis buffer; after protein quantiﬁcation, tissue
extracts were immunoblotted for p-eNOS, p-Akt, total
eNOS, and total Akt.
Adenoviral VEGF-Driven Ear Angiogenesis
AKR/J white mice were fed a high-fat diet or a control diet
(normal chow) and received intradermal injection of recom-
binant adenoviruses (1  108 plaque-forming units) encoding
murine VEGF-A164 (AdVEGF) into the left ear or control Cre
recombinase (AdCre) into the right ear. After 5 days, ears were
photographed and then removed from euthanized mice. Fixed
cryosections (7 mm thick) were immunostained with mono-
clonal rat anti-mouse CD31 antibody (BD Biosciences) and
Alexa Fluor 488econjugated anti-rat IgG antibody (Life
Technologies). Fluorescent images were obtained on a Zeiss
Axioskop microscope (Carl Zeiss Microscopy, Jena, Ger-
many), and CD31-positive staining was quantiﬁed with
ImageJ software version 1.42a (NIH, Bethesda, MD).
Hindlimb Ischemia and Laser Doppler Imaging
To induce ischemia, in both control mice and in mice fed a
high-fat diet, the femoral artery and vein were ligated just
below the inguinal ligament at the level of entry into the1563
Mehra et althigh and at the level of the popliteal artery. The intervening
segment was excised, and other branches of the femoral
artery (including the profunda and the superﬁcial and deep
femoral branches) were cauterized. Laser Doppler imaging
for blood-ﬂow analysis was performed by placing the
Doppler probe directly on the gastrocnemius muscle at 3
days, 1 week, and 3 weeks. Data are expressed as a ratio of
ﬂow in the ischemic hindlimb to ﬂow in the nonischemic
control (contralateral) hindlimb.
Matrigel in Vitro Cord Formation
HUVECs at passage 4 (5  105 cells) were suspended in
growth factorereduced Matrigel (BD Biosciences) contain-
ing medium with or without various growth factors, fatty
acids, and inhibitors. Cells were incubated for 12 to 16 hours
at 37C, after which cord area, length, and branch points were
quantiﬁed using Metamorph software version 7.1 (Molecular
Devices, Sunnyvale, CA) as described previously.10
NO Chemiluminescence
Conﬂuent BAECs were treated with solvent control, PA, or
C2 ceramide in serum-free medium for 4 hours. The me-
dium was changed, and after 30 minutes of incubation in
fresh medium the supernatants were collected as a presti-
mulation sample. VEGF-containing medium was then
added, and after 45 minutes of incubation the supernatants
were collected as a poststimulation sample. Levels of NOx
(deﬁned as NO2
, NO3
, and nitrosothiols) were determined
by NO-speciﬁc chemiluminescence as described previ-
ously.11 In brief, cells were lysed, total protein was quan-
tiﬁed, and NOx levels were normalized to total protein.
Immunoblotting and Immunoprecipitation
BAECs treated with solvent control, PA, or C2 ceramide were
treated with VEGF (or bradykinin), and lysates generated in
radioimmunoprecipitation assay buffer were subjected to
immunoblotting as described previously.12 For VEGFR2
immunoprecipitation and for coimmunoprecipitation, treated
BAECs were lysed in 50 mmol/L Tris-HCl (pH 7.4), 5 mmol/L
Na4P2O7, 50 mmol/L NaF, 1 mmol/L Na3VO4, 1 mmol/L
dithiothreitol, 0.5% NP-40, and complete protease inhibitor
(cOmplete; Roche Diagnostics, Indianapolis, IN). Experimental
molecules (VEGFR2, eNOS, and PP2A) were immunopre-
cipitated overnight with excess antibody; eluted immunopre-
cipitates were resolved by SDS-PAGE, then subjected to
immunoblotting as described previously.12 The antie
phosphorylated amino acid antibody speciﬁcities were eNOS-
Ser1179, Akt-Ser473, ERK1-Thr202/ERK2-Tyr204.
Ceramide Quantiﬁcation
Solvent control-treated or PA-treated BAECs were trypsi-
nized, washed, and pelleted into glass vials. Lipids were1564extracted as described previously,13 dissolved in chloroform/
methanol (2:1, v/v), and subjected to liquid chromatogra-
phyetandem mass spectrometry (LC-MS/MS) analysis.
Total ceramide content was expressed as the sum of indi-
vidual species, normalized to cell number. For aortic tissue,
adventitial fat was removed from excised aortas, lipids were
extracted, and tissue ceramide fractions were measured with
the same technique, normalized to sample weight.
Annexin V Apoptosis Assay
BAECs or HUVECs were treated with PA or with heat
(70C) and then were trypsinized, washed, resuspended in
annexin V binding buffer (BD Biosciences), and stained
with annexin Veﬂuorescein isothiocyanate. Flow cyto-
metric analysis was performed using a FACSCalibur system
(BD Biosciences); 5000 events were acquired and analyzed
per experimental sample.
Proliferation Assay
BAECs were seeded at 5000 cells per well for 24 hours in
complete medium, serum-starved in 0.1% BSAeDulbecco’s
modiﬁed Eagle’s medium, pretreated with PA, and stimu-
lated with 25 to 50 ng/mL VEGF. Cell proliferation was
measured at 0, 24, and 48 hours after VEGF treatment using
a CellTiter-Glo assay (Promega, Madison, WI) based on
ATP content in quadruplicate wells.
PP2A Phosphatase Activity Assay
PP2A activity was measured using a PP2A immunopre-
cipitation phosphatase assay kit (EMD Millipore) accord-
ing to the manufacturer’s recommendations. In brief, PP2A
was immunoprecipitated from BAEC lysates with anti-
PP2A C subunit antibody (clone 1D6). Phosphopeptide
substrate (KRpTIRR) was added to washed immunopre-
cipitates in Ser/Thr assay buffer and incubated for 10 mi-
nutes at 30C, after which the amount of phosphate
released from the phosphopeptide was measured by
absorbance at 650 nm using malachite green solution and
phosphate standard. The amount of released phosphate was
normalized to the amount of PP2A C subunit detected by
immunoblotting. Speciﬁcity of the PP2A was conﬁrmed by
blocking PP2A activity with 100 nmol/L OkA added both
to cells and to the lysis buffer.
MicroSPECTeCT Imaging
MicroSPECTeCT hindlimb imaging, detecting a 99mTc-
labeled chelate-peptide conjugate containing an RGD (Arg-
Gly-Asp) motif (GE Healthcare, Little Chalfont, UK) targeted
at the activated avb3 integrin was performed on ischemic and
contralateral nonischemic hindlimbs as described previously.14
In brief, animals were injected intravenously with 1 mCi of the
99mTc-labeled chelateepeptide conjugate containing an RGDajp.amjpathol.org - The American Journal of Pathology
Ceramide and Endothelial VEGF Resistancemotif (99mTc-NC100692; GE Healthcare) targeted at the acti-
vated avb3 integrin at 4 days and 4 weeks after surgical in-
duction of hindlimb ischemia. Our previous experiments have
validated speciﬁc signals and counts from 99mTc-NC100692,
relative to a control scrambled peptide (99mTc-AH-111744-01)
that yields minimal background counts in angiogenic tissues.14
Imaging with the control peptide conﬁrmed these prior results
(data not shown).
Imaging was performed with a hybrid dual-head micro-
SPECTeCT small-animal scanner (Gamma Medica X-
SPECT; Siemens Healthcare, Malvern, PA) equipped with
1-mm pinhole collimators. Animals were placed on the
animal bed in the supine position, with hindlimbs secured in
an extended position. At 1 hour after radiotracer injection,
mice underwent SPECT imaging (32 projections, 60 sec-
onds/projection per scanner head) with a 20% energy
window centered at 140 keV. This was followed by high-
resolution anatomical CT imaging (512 projections at 50
kVp/600 mA energy).
MicroSPECT and CT images were reconstructed as
described previously.14 In brief, MicroSPECT images were
ﬁltered, fused with microCT images, and converted to
Analyze 7.5 ﬁle format (Mayo Foundation, Rochester, MN).
The relative tracer uptake within the hindlimb soft tissues
was quantiﬁed using semiautomated software (BioImage
Suite version 2.6; Yale University School of Medicine, New
Haven, CT). Complex irregular volumes of interest (VOIs)
were generated from the microCT images and were regis-
tered with the microSPECT images. These complex regions
included only soft-tissue structures from the hindlimb;
skeletal structures were removed during the segmentation
process. The object map was applied to the corresponding
microSPECT image to determine mean counts in each VOI.
The radiotracer activity from the ischemic (I) proximal and
distal hindlimb was normalized by the contralateral non-
ischemic (NI) proximal and distal hindlimb, respectively, to
compute I/NI ratios.
Statistical Analysis
Student’s t-test or repeated measures analysis of variance
were used, as applicable. P < 0.05 was considered
signiﬁcant.
Results
PA Attenuates Basal and VEGF-Induced NO Production
To determine whether PA affects endothelial NO produc-
tion, BAECs were pretreated for 3 hours with vehicle con-
trol or BSA-conjugated PA, before measurement of basal
and 100 ng/mL VEGF-stimulated NO by chem-
iluminescence. We observed a 50% reduction in basal NO
production in cells treated with 100 mmol/L PA, and an
abrogation of the VEGF-induced augmentation in NO pro-
duction (Figure 1A). These ﬁndings demonstrate thatThe American Journal of Pathology - ajp.amjpathol.orgarterial ECs exposed in vitro to PA levels even below those
observed in individuals with metabolic syndrome exhibit
diminished basal and VEGF-stimulated NO production.
PA Impairs VEGF-Induced Angiogenesis in Vitro
VEGF plays a signiﬁcant role in angiogenic responses
through its modulation of eNOS activity and NO produc-
tion.15 The Matrigel cord formation assay is an accepted
in vitro model for study of critical endothelial features
required for angiogenesis (ie, those of matrix plus growth
factor-driven EC proliferation and migration). HUVECs
were plated in growth factorereduced Matrigel to assess the
effects of PA on angiogenic cord formation. Cord length,
area, and branch point (node) numbers were assessed after
12 hours in vehicle control or 100 mmol/L PA, with and
without 100 ng/mL VEGF. We observed a marked reduc-
tion in visible VEGF-induced cord formation in the
PA-treated wells (Figure 1C); quantiﬁcation indicated
approximately 50% reduction in all angiogenesis correlates
(Figure 1D). At PA concentrations of 300 mmol/L, cord
formation was absent (data not shown).
To ensure that the loss of BAEC NO production and
HUVEC-based angiogenic cord formation was not a
consequence of PA-induced apoptosis, PA-treated BAECs
(100 and 300 mmol/L for 3 hours) and HUVECs (100 and
300 mmol/L for 16 hours) were analyzed by ﬂuorescence-
activated cell sorting for annexin V binding. The 3-hour and
16-hour time points were chosen to correlate with those
used in BAEC signaling and HUVEC Matrigel assays,
respectively. Annexin V positivity in PA-treated, non-
permeabilized BAECs and HUVECs was negligible,
compared with heat-induced apoptotic controls (Figure 1B).
Thus, the relative NO deﬁciency states in PA-treated ECs
was not a consequence of PA-induced EC apoptosis.
However, PA signiﬁcantly reduced BAEC proliferation in
response to VEGF (Figure 1E), suggesting that PA may
impair proangiogenic proliferative signaling downstream of
VEGFR2.
PA Inhibits VEGF-Induced Akt and eNOS
Phosphorylation
VEGFR2, the dominant VEGF receptor in mature endothe-
lium, is a major mediator of the mitogenic, angiogenic, and
permeability-enhancing effects of VEGF. The most proximal
step in the VEGF signaling cascade is ligand-induced
VEGFR2 dimerization and trans-autophosphorylation. To
assess whether PA-induced defects in VEGF-stimulated NO
production are a consequence of impaired VEGFR2 activa-
tion, BAECs were treated with 0 (vehicle control) or 100
mmol/L PA. At 3 hours, cells were stimulated with 50 ng/mL
VEGF for 10 minutes, after which lysates were recovered for
VEGFR2 immunoprecipitation and phosphotyrosine immu-
noblotting. VEGF-stimulated VEGFR2 tyrosine phosphor-
ylation was not impaired by 100 mmol/L PA (Figure 2A),1565
Figure 1 Effect of PA on VEGF-induced EC NO
release and angiogenic cord formation. A: Basal
and VEGF-induced NO release in BAECs. BAECs were
treated with 100 mmol/L PA or solvent control for
4 hours, followed by 100 ng/mL VEGF or control for
45 minutes, after which NOx was measured by
chemiluminescence. B: PA does not induce EC
apoptosis. BAECs or HUVECs were treated with
vehicle control or PA at 100 or 300 mmol/L for 3
and 16 hours, respectively. For positive apoptotic
controls, cells were heat shocked at 70C for 5
minutes before annexin V staining. C: PA effect on
Matrigel cord formation. HUVECs were treated with
100 mmol/L PA and 100 ng/mL VEGF. D: Meta-
morph analysis was used to quantify cord length,
area, and branch points in representative ﬁelds. E:
PA pretreatment impairs VEGF-induced prolifera-
tion. BAECs were seeded in 96-well plates, serum
starved, and pretreated with 100 mmol/L PA before
stimulation with VEGF. Cell proliferation was
measured using a CellTiter-Glo assay in quadru-
plicate wells. Data are expressed as means  SEM
(A and D) or as means  SD (E) and are repre-
sentative of three independent experiments. *P <
0.05 versus VEGF alone; yP < 0.05, yyP < 0.005
versus control. Original magniﬁcation, 400.
Mehra et aldespite the profound effect of this PA treatment on stimulated
NO production (Figure 1A). There was no PA effect on total
VEGFR2 levels. Higher PA concentrations did have an
inhibitory effect on VEGFR2 phosphorylation (data not
shown). However, because all of the PA-induced defects (ie,
NO production and angiogenic cord formation, as well as
distal kinase signaling, which is discussed below) could be
reproducibly detected in the presence of 100 mmol/L PA, we
focused on those more distal consequences of PA on the
VEGF signaling cascade. For further experiments, PA
treatments were at 50 or 100 mmol/L.
VEGFR2-Tyr1175 is an autophosphorylation docking site
that initiates PLC-geERK1/2 and PI3KeAkt pathway acti-
vation. AkteeNOS and ERK activation are all critical in a
variety of growth factorestimulated angiogenic responses at
the cellular and tissue level, including cell migration, pro-
liferation, antiapoptosis, and tissue remodeling. We therefore
assessed the effect of PA on VEGF-stimulated phosphory-
lation on the following critical kinase activation sites: Akt-
Ser473, eNOS-Ser1179, and ERK1-Thr202/ERK2-Tyr204. As
before, BAECs were treated with 0 (vehicle control) or 100
mmol/L PA for 3 hours, followed by 10 minutes of 0 (control)
or 50 ng/mL VEGF treatment, after which lysates were1566recovered for immunoblotting. We observed a dose response
from 10 to 100 mmol/L for this PA-induced inhibition
(Figure 2B). PA at 100 mmol/L, a concentration that does not
affect VEGF-stimulated receptor phosphorylation, imparted
a strong inhibition of VEGF-induced Akt, eNOS, and ERK
activation (Figure 2, CeE). These results indicate that acti-
vation, as determined by activation site phosphorylation in
multiple key kinases downstream of VEGFR2 signaling, is
impaired in PA-exposed ECs.FFA-Induced eNOS Activation Defect Is Not
VEGF-Speciﬁc
Because the PA-induced inhibitory effect on VEGF-
stimulated NO production is largely the result of
ceramide-activated, PP2A-mediated (discussed below) Akt
and eNOS dephosphorylation, we expected that similar
biochemical changes would be observed in the context of
other eNOS agonists. Bradykinin-stimulated eNOS phos-
phorylation was greatly reduced in PA-exposed cells
(Figure 2F). The diversity of signaling defects, both to
receptor tyrosine kinase and G protein-coupled receptorajp.amjpathol.org - The American Journal of Pathology
Figure 2 A: Effect of PA on stimulus-dependent kinase activation. BAECs were pretreated for 3 hours with vehicle control or 100 mmol/L PA, followed by
0 or 100 ng/mL VEGF treatment for 10 minutes. Effect of PA on VEGF-induced VEGFR2 tyrosine phosphorylation, by VEGFR2 immunoprecipitation and
phosphotyrosine immunoblotting. B: Dose response of VEGF-induced Akt and eNOS phosphorylation after pretreatment with 0, 10, 50, or 100 mmol/L PA. All
samples were then treated with 100 ng/mL VEGF for 10 minutes. C: Representative immunoblot showing effects of PA on phosphorylation of Akt, eNOS, and
ERK1/2. D: Densitometry of Akt phosphorylation at Ser473. E: Densitometry of eNOS phosphorylation at Ser1179. F: Effect of PA on bradykinin-induced
phosphorylation of eNOS at Ser1179. Data are expressed as means  SEM. n Z 3 (D); n Z 5 (E). *P < 0.05. IB, immunoblotting; IP, immunoprecipitation.
Ceramide and Endothelial VEGF Resistanceagonists, supports a state of extensive endothelial dysfunc-
tion induced by PA.
PP2A Mediates PA-Induced Impairment in
VEGF-Stimulated Angiogenic Kinase Activation
As with most molecules that are dynamically regulated by
phosphorylation, the aforementioned kinase activation
states are a net consequence of phosphorylation and
dephosphorylation. Because the AkteeNOS and ERK
pathways diverge proximally, we investigated whether the
relative lack of activation of all three kinases is a conse-
quence of PA-induced enhanced dephosphorylation. Akt,
eNOS, and ERK 1/2 are all substrates of PP2A, an abun-
dant protein known to regulate these kinases16e18 by
colocalizing in speciﬁc cellular compartments. That is,
augmented PP2A interaction results in kinase inactivation.
We therefore performed a series of coimmunoprecipitation
experiments. PA exposure dramatically enhanced PP2A
association with eNOS, ERK and Akt (Figure 3A and
Supplemental Figure S1). These ﬁndings are consistent
with PA impairing endothelial responses to VEGF through
promoting PP2A interactions with critical enzymatic sub-
strates, thereby reducing NO production. In addition, we
performed PP2A phosphatase activity assays, using a
ﬂuorimetric phosphopeptide substrate (KRpTIRR). Both
PA and ceramide (discussed below) induced a sustained,
signiﬁcant increase in EC PP2A enzymatic activity (data
not shown).
To further verify the role of PP2A in relevant kinase
regulation, we tested whether the phosphatase inhibitor OkA,
a speciﬁc PP2A inhibitor at the dose of 100 nmol/L, prevents
the aforementioned defects observed in PA-exposed,The American Journal of Pathology - ajp.amjpathol.orgVEGF-treated BAECs. The BAECs were pretreated with
OkA for 30 minutes before 3-hour exposure to 100 mmol/L
PA, after which cells were treated with 0 or 50 ng/mL
VEGF for up to 20 minutes. OkA prevented the reduction in
VEGF-stimulated eNOS-Ser1179 phosphorylation observed
in PA-exposed cells (Figure 3B). Similar results were ob-
tained when assessing Akt-Ser473 phosphorylation (data not
shown). These rescue experiments support the notion that
the PA-induced defects in VEGF signaling occur through
activation of endothelial PP2A.
PA Generates Endothelial Ceramides
Saturated fat elevates ceramide levels in liver and muscle,
with some fat-induced insulin signaling abnormalities
prevented by ceramide synthesis inhibition.19 Further-
more, PP2A is one of the ceramide-activated protein
phosphatases.20 We therefore investigated whether PA-
induced ceramide generation is a central component of
the endothelial signaling defects described above. Indi-
vidual ceramide species in control and PA-treated BAECs
were measured by LC-MS/MS; total ceramide content
was expressed as the sum of individual species and
normalized to cell number. We observed a twofold and
sixfold ceramide increase in BAECs exposed to PA for 3
and 18 hours, respectively (Figure 4, A and B). Most of
the ceramide elevation is in the early species C16, sug-
gesting generation via the de novo pathway, in which
C16 is generated by a series of enzymatic reactions on
palmitoyl CoA (C16:O) binding to serine. The augmented
endothelial ceramide levels are greater than those re-
ported to cause signiﬁcant cellular and pathological
abnormalities.211567
Figure 3 Role of PP2A in PA-induced VEGF signaling defect. A: Coimmunoprecipitation of PP2A and eNOS, ERK, and Akt in BAECs. For densitometric
quantiﬁcation, the control ratio was deﬁned as 100%. The reverse coimmunoprecipitations are presented in Supplemental Figure S1. B: Effect of PP2A in-
hibition on VEGF-induced eNOS-Ser1179 phosphorylation. BAECs were pretreated for 4 hours with 100 mmol/L PA or control in the presence or absence of 100
nmol/L PP2A inhibitor OkA. Cells were then treated with 100 ng/mL VEGF for 0, 5, or 20 minutes. For densitometric quantiﬁcation of p-eNOS/total eNOS in
VEGF 5-minute samples, the control ratio was deﬁned as 100%. Data are expressed as means  SEM. Blots and data are representative of three independent
experiments. **P < 0.01.
Mehra et alPA-Induced Endothelial Ceramide Generation Causes
Defects in VEGF Signaling and VEGF-Induced
Angiogenic Cord Formation
In determining whether the ceramide generation in PA-
exposed cells is responsible for the aforementioned endo-
thelial defects, we ﬁrst attempted to reproduce those defects
by raising intracellular ceramide levels with the short-chain,
cell-permeable C2 ceramide. The C2 ceramide treatment
resulted in abrogation of VEGF-induced eNOS-Ser1179 and
Akt-Ser473 phosphorylation, as well as in reduction of basal
levels of p-eNOS and p-Akt (Figure 4C). The expected
reduction in VEGF-stimulated NO production was also
detected (Figure 4D), similar to that observed in the pres-
ence of PA (Figure 1A). Furthermore, C2 ceramide treat-
ment of HUVECs prevented all aspects of VEGF-induced
cord formation (area, length, and branch points) in the
Matrigel in vitro assay (Figure 4, E and F), similar to the PA
effect. Thus, the endothelial defects in VEGF responses
induced by PA can all be reproduced by raising intracellular
ceramide levels with C2 ceramide.
In our model, PA exposure leads to the endothelial
accumulation of excess palmitoyl CoA moieties, with
consequent de novo ceramide synthesis. The rate-limiting
step in this biosynthetic pathway is catalyzed by serine
palmitoyl transferase (SPT), generating ketosphinganine
from palmitoyl CoA and serine. Myriocin is a potent and
speciﬁc SPT inhibitor22 that binds to both the LCB1 and1568LCB2 subunits.23 To investigate whether inhibiting
de novo ceramide synthesis protects ECs from PA-induced
VEGF signaling defects, BAECs were pretreated with 100
nmol/L myriocin for 30 minutes before the 3-hour expo-
sure to PA, followed by VEGF stimulation and kinase
activation analysis. Myriocin partially prevented the PA-
induced inhibition of VEGF-stimulated eNOS phosphor-
ylation (Figure 5A). Again, as expected given these
signaling results, myriocin partially rescued VEGF-
stimulated angiogenic cord formation by PA-treated
HUVECs in the Matrigel in vitro assay (Figure 5B). We
observed approximately 50% reduction of the PA-induced
inhibition of all three aspects of cord formation
(Figure 5C). Myriocin largely (but incompletely) pre-
vented PA-induced increases in C16 and total ceramide
generation (Supplemental Figure S2) (P < 0.007 versus
control or PA), which explains the signiﬁcant but incom-
plete rescue of VEGF-stimulated responses.
High-Fat Feeding Impairs Responses to VEGF in Vivo
To investigate the effects of saturated fatty acids on VEGF
responses in vivo, AKR/J mice were fed a high-fat diet, such
that 60% of the caloric intake was derived from saturated fats
(and predominantly from PA). Dietary fat composition de-
termines the pattern of FFA elevation.24 After 2.5 weeks of
high-fat feeding, there was a 71% increase in FFA levels,
relative to control-chow feeding (Figure 6A). Similar FFAajp.amjpathol.org - The American Journal of Pathology
Figure 4 Comparison of ceramide-induced and
PA-induced effects on VEGF-stimulated NO pro-
duction and angiogenic cord formation. A and B:
BAECs were treated with 100 mmol/L PA for 4 hours
(A) or 18 hours (B), after which cells were recov-
ered, lipids were dissolved in methanol, and cer-
amide fractions were measured by LC-MS/MS. Total
ceramide content (ie, the sum of the individual
species) was normalized to cell number. C and D:
Directly raising intracellular ceramide with 30
mmol/L C2 ceramide mimics defects caused by
exposure to 100 mmol/L PA in 100 ng/mL VEGF-
induced p-Akt-Ser473 and p-eNOS-Ser1179 (C) and
NO production measured by chemiluminescent NOx
analysis (D). Blots are representative of three in-
dependent experiments. E: Similar effects were
seen in Matrigel cord formation. Images for VEGF
plus ethanol solvent control or dimethyl sulfoxide
control were identical to the VEGF image (data not
shown). F: Cord length, area, and branch points
were quantiﬁed with Metamorph analysis. Images
and quantiﬁcation are representative of three in-
dependent experiments. Data are expressed as
means  SEM. **P < 0.01, ****P < 0.0001 versus
control or VEGF. Original magniﬁcation, 400.
Ceramide and Endothelial VEGF Resistanceelevations were observed in high-fat-fed C57BL/6J mice
(discussed below). There was a minimal and statistically
nonsigniﬁcant increase in weight of the high-fat-fed animals
(data not shown). Most models of dietary insulin resistance
involve substantially longer periods of high-fat feeding. Our
goal in the present study was to develop a model with
elevated serum FFA levels without signiﬁcant insulin resis-
tance, and so the duration of fat-feeding was abbreviated.
To recapitulate the in vitro VEGF signaling defect in vivo,
1 mg recombinant VEGF-A165 was infused intravenously
into mice fed a high-fat or a control diet. After 10 minutes,
the animals were perfused with 1 mmol/L Na3VO4 for 3
minutes; aortas were then harvested and homogenized, after
which p-eNOS and p-Akt immunoblotting was performed.
The loss of VEGF induced aortic eNOS-Ser1177 phosphor-
ylation in high-fat-fed animals (Figure 6B). Although less
profoundly and less consistently reduced than p-eNOS, Akt-
Ser473 phosphorylation was less robust in aortas obtained
from mice fed a high-fat diet. Because the aortic homoge-
nates contain a combination of cells and because Akt is
ubiquitously expressed, whereas eNOS is endothelialThe American Journal of Pathology - ajp.amjpathol.orgspeciﬁc within the aorta (and therefore is VEGF respon-
sive), more impressive effects of high-fat feeding on eNOS
phosphorylation were expected. The fat-induced inhibition
of VEGF-stimulated eNOS activation was similar to that
observed with PA-exposed ECs in vitro.
To extend these aortic signaling experiments to VEGF-
induced angiogenesis in vivo, 1  108 viral particles of
recombinant adenovirus encoding VEGF (AdVEGF) or Cre
recombinase control (AdCre) were injected intradermally
into the left and right ears, respectively, of AKR/J mice. Ears
were harvested at 5 days, at which point VEGF-induced
angiogenic responses and capillary leak occur. A robust
VEGF response was observed in mice fed the control diet
(Figure 6C). The thickness and length of the neovessels, as
well as the erythema (capillary leak), were attenuated in the
ear of mice fed a high-fat diet (Figure 6C). This observation
was conﬁrmed by CD31/PECAM immunoﬂuorescent
staining, with far fewer, thinner and shorter CD31/PECAM-
positive (capillary) structures in the ear of mice fed a high-
fat diet (Figure 6D). This difference was quantiﬁed by
image analysis, which conﬁrmed a 45% reduction in1569
Figure 5 Effect of ceramide synthesis inhibi-
tion on PA-induced VEGF signaling defects. A:
Effect of treatment with 100 nmol/L myriocin, a
serine palmitoyltransferase (ceramide synthesis)
inhibitor, on VEGF-induced p-eNOS Ser1179 in
BAECs exposed to 100 mmol/L PA or control for 4
hours. B: Effect of myriocin on 100 ng/mL VEGF-
induced Matrigel cord formation in HUVECs in the
presence or absence of 100 mmol/L PA  100
nmol/L myriocin. C: Cord length, area, and branch
points were quantiﬁed with Metamorph analysis.
Blots, images, and quantiﬁcation are representa-
tive of three independent experiments.
**P < 0.01. Original magniﬁcation, 400. Myr,
myriocin.
Mehra et alVEGF-induced capillary formation in the ear of mice fed a
high-fat diet, compared with the controls (Figure 6E). In this
model, AdVEGF is a potent stimulus to angiogenesis, with
extensive capillary leak and capillary network formation.
Although signiﬁcant, the reduction in angiogenesis
observed in mice fed a high-fat diet likely underestimates
the effect of FFA on VEGF-induced endothelial responses,
including angiogenesis in more physiological settings.
High-Fat Feeding Increases Aortic Ceramide and
Impairs Ischemia-Induced Arteriogenesis
Because the in vitro ﬁndings demonstrated that PA-induced
ceramide generation is mechanistically linked to the
signaling defects noted, we measured ceramide levels in
aortic tissue recovered from mice fed a high-fat or control
diet for 2.5 weeks. We observed an elevation in early cer-
amide species (C16, C18, and C22) in aortas from mice fed
a high-fat diet, relative to control mice (Figure 7A). These
differences, although modest, were statistically signiﬁcant
and, we believe, biologically important. The pattern of
ceramide elevation is consistent with de novo generation
from excessive palmitoyl CoA, similar to that observed for
EC ceramide generation in vitro.
Ischemia-driven neovessel formation involves endothelial
responses to multiple angiogenic growth factors, including
VEGF. Murine hindlimb ischemia is an established model of
ischemia-driven angiogenesis and arteriogenesis. Of the1570several different technical approaches, we chose the most
severely ischemic and hypoxic model, which provides a potent
stimulus to VEGF-induced neovessel formation. The femoral
artery and vein of 2.5 weeks high-fat-fed and control C57BL/
6J mice were ligated just below the inguinal ligament and at
the level of the popliteal artery, after which this entire vascular
segment was removed. Hindlimb perfusion was serially
measured on postoperative days 3, 7, and 21, using a laser
Doppler vascular probe, placed directly on the gastrocnemius
muscle, both in the ischemic and the contralateral normal
hindlimb. Data are expressed as ischemic/normal ﬂow ratios.
Angiogenic recovery was slower in the mice fed a high-fat
diet, compared with controls, and the most dramatic differ-
ences were observed at the earlier postoperative time points
(Figure 7B). This is consistent with previous reports that, in
animal models of severe limb ischemia, VEGF levels rise
rapidly after ischemia induction and taper quickly.25,26 The
ﬂows at early time points (3 and 7 days) are most reﬂective of
angiogenic responses, whereas contributions of collateral
arteriogenesis occur at later time points.
To obtain a more precise analysis of ischemia-induced
arteriogenesis at later time points, we also performed
in vivo hybrid SPECTeCT imaging, using the 99mTc-
labeled RGD (Arg-Gly-Asp) peptide NC100692 (GE
Healthcare), which speciﬁcally binds activated avb3
integrin with high afﬁnity.27 This cyclic peptide has been
used to target peripheral neovascularization in response
to ischemia in models similar to those describedajp.amjpathol.org - The American Journal of Pathology
Figure 6 Effect of high-fat feeding (saturated
fatty acid) on VEGF-induced angiogenic kinase
phosphorylation and angiogenesis in vivo. A:
AKR/J mice were fed a high-fat diet (60% satu-
rated fatebased calories) or a normal chow diet for
3 weeks. Plasma nonesterifed FFAs were measured
by an acyl-CoA oxidase-based colorimetric assay.
B: VEGF-A165 (1 mg) was infused intravenously for
10 minutes, after which aortas were harvested and
homogenized, and tissue lysates were immuno-
blotted for p-Akt-Ser473, p-eNOS-Ser1177, total Akt,
and total eNOS. Each lane represents an individual
mouse, and blots are representative of three in-
dependent experiments. C: AdVEGF (left ear) or
AdCre (right ear) were injected intradermally into
high-fat-fed or control mice. Ears were photo-
graphed at 5 days for vascularity and vascular leak.
D and E: Ears were ﬁxed and immunostained for
CD31/PECAM expression (D), and data were quan-
tiﬁed with ImageJ analysis, normalizing AdVEGF
(left ear) pixels with the corresponding AdCre
(right ear) pixels (E). The control ratio was deﬁned
as 100%. Data are expressed as means  SEM.
*P < 0.05, ***P < 0.001. Original magniﬁcation,
400.
Ceramide and Endothelial VEGF Resistancehere.14,28 The semiautomated quantitative approach, with
CT-generated VOIs in which relative radiotracer activity is
serially determined by micro-SPECT imaging, has been
validated previously.14 Both avb3 expression and activity
levels are increased in angiogenic settings, where this
integrin plays a role in cell migration, proliferation, and
survival29 and can be VEGFR2-associated.30
In our severe ischemia model, serial hindlimb imaging
was performed on the same animals over a 4-week post-
operative period. Representative microSPECTeCT images
show the CT-generated VOIs and the avb3especiﬁc radi-
oligand uptake in those VOIs, at 4 days and 4 weeks after
femoral artery ligation in high-fat-fed and control mice
(Figure 7C). Quantiﬁcation was expressed as the ratio of
ligand uptake in the ischemic to the contralateral non-
ischemic hindlimb in the proximal hindlimb (Figure 7D).
Imaging at early time points is difﬁcult to interpret with
this ligand, because the inﬂammation induced both by
surgery and by ischemia promotes recruitment of leuko-
cytes (largely monocytes and macrophages) expressing
avb3. As expected, ligand uptake was high, and differences
between control and mice fed a high-fat diet were obscured
at 4 days. However, proximal hindlimb imaging at 4 weeks
demonstrated a signiﬁcant reduction in activated avb3
expression in the mice fed a high-fat diet. This later time
point is most reﬂective of differences in collateral arte-
riogenesis, and is more easily seen proximally. There was
also a nonsigniﬁcant trend toward less uptake at later time
points in the distal hindlimb, but this was less dramatic
(data not shown). The two techniques, laser Doppler im-
aging over the distal hindlimb at early time points, and
proximal avb3 SPECT imaging at later time points, thusThe American Journal of Pathology - ajp.amjpathol.orgreﬂect impaired microvessel angiogenic and collateral
arteriogenic responses, respectively, in short-term high-fat-
fed animals. Both adaptive responses to ischemia are
impaired, and the two techniques are complementary.
Aortic Ceramides Are Reduced and VEGF Responses Are
Restored in High FateFed SPT Haploinsufﬁcient Mice
Because the PA-induced alterations in VEGF-induced Akt
and eNOS phosphorylation are ceramide-mediated in vitro,
we used a genetic model to address the importance of cer-
amide generation in vivo. The Sptlc2/þ mouse is hap-
loinsufﬁcient in endogenous ceramide synthesis.8 For
conﬁrmation in vascular tissue, Sptlc2/þ mice were fed a
high-fat diet, as above, for 2.5 weeks, after which aortas
were harvested for individual ceramide species measure-
ment by LC-MS/MS. Aortic ceramide levels in Sptlc2þ/þ
and Sptlc2/þ mice fed normal chow were essentially
identical (Figure 8A). However, the increase in ceramide
metabolites observed in high-fat-fed Sptlc2þ/þ mice was
largely (>60%) prevented in Sptlc2/þ mice (Figure 8B).
This relative impairment in fat-induced ceramide synthesis
provided an opportunity to correlate the VEGF resistance
mechanism (ceramide-driven) that we established in vitro
with the in vivo impairment described above. Sptlc2/þ
mice were relatively protected from the fat-induced inhibi-
tion of VEGF signaling, as observed in aortic tissue p-Akt
and p-eNOS immunoblots after VEGF IV infusion
(Figure 8, CeE) and in ear angiogenesis analysis after
AdVEGF injection (Figure 8, F and G). These observations
demonstrate that ceramide generation is fundamental to the
VEGF resistance state induced by high-fat feeding in vivo.1571
Figure 7 Effect of high-fat feeding on vascular
ﬂow recovery to hindlimb ischemia. A: Aortas were
recovered from C57BL/6J mice after 2 weeks of
normal chow (white bars) or a high-fat (gray bars)
diet. Adventitial fat was carefully excised, and
tissue homogenates were analyzed for ceramide
content by LC-MS/MS. B: C57BL/6J mice were fed
normal chow or a high-fat diet for 2.5 weeks, after
which unilateral (left) femoral artery ligation was
performed. Laser Doppler imaging was performed
at 3 days, 1 week, and 3 weeks after femoral artery
ligation over the gastrocnemius muscle in C57BL/
6J mice fed normal chow or a high-fat diet for 2.5
weeks. Left/right ﬂow ratios refer to ischemic/
nonischemic hindlimb. C: Arteriogenic response to
hindlimb ischemia measured by microSPECTeCT in
C57BL/6J mice fed normal chow or a high-fat diet
at 4 days and 4 weeks after ligation. Representa-
tive images show the ischemic (I) left hindlimb
and the control nonischemic (N) right hindlimb; a
99mTc-labeled radiotracer was targeted at activated
avb3. The microCT images were segmented to
generate multiple VOIs (top row). Contours of
these VOIs are superimposed on representative
microCT images (middle row). These complex VOIs
were applied to registered microSPECT images
(bottom row), to determine mean counts in the
proximal hindlimb VOI (bold outline). The quan-
tiﬁcation of activated avb3 is reﬂected in the
colorimetric intensity scale (bottom row). D:
Quantitative mean counts in ischemic proximal
hindlimb VOI were normalized to the correspond-
ing contralateral nonischemic hindlimb VOI and
expressed as the I/N uptake ratio. Arrows point to
the VOI in the ischemic hindlimb where the dif-
ference in the activated aVb3 is apparent between
control and fat-fed mice at 4 weeks after ligation.
Data are expressed as means  SD (A) or means 
SEM (B and D) and are representative of three in-
dependent experiments. n Z 10 mice per group
(A and B); and n Z 5 per group (D). *P < 0.05,
**P < 0.01.
Mehra et alDiscussion
Increased plasma FFA is one of the hallmarks of insulin
resistance. Endothelial function, largely deﬁned as
endothelium-dependent vasodilation, is impaired in meta-
bolic syndrome. Endothelial dysfunction has a strong and
independent predictive value for atherosclerosis and for
cardiovascular events.2 A primary, causative role for FFA in
cardiovascular disease has been suggested by experimental
studies in which endothelial dysfunction has been induced
by raising FFA levels in healthy individuals.31 Paradoxi-
cally, systemic VEGF levels are elevated in atherosclerosis
and in type 2 diabetes,6 states in which endothelium-
dependent vasodilation is impaired. Thus, it is reasonable1572to hypothesize that there exists a state of VEGF resistance,
at the level of the endothelium, analogous to (but not
necessarily mechanistically identical to) insulin resistance
states. In the present study, we examined the effect of PA,
one of the fatty acids most commonly found in the western
diet, on endothelial responses to VEGF in vitro and in vivo.
ECs exposed to PA, even at levels below those commonly
observed in metabolic syndrome, have markedly diminished
levels of VEGF-induced eNOS, Akt, and ERK phosphory-
lation at critical activation sites, despite preserved VEGF-
stimulated VEGFR2 tyrosine phosphorylation.
Reduced eNOS (and Akt) phosphorylation in response to
VEGF would be expected to result in less EC NO produc-
tion, as we observed (Figure 1). It is possible thatajp.amjpathol.org - The American Journal of Pathology
Figure 8 Effect of SPT haploinsufﬁciency on aortic ceramide levels and angiogenic responses. A and B: Accumulation of ceramide metabolites in aortas of
Sptlc2/þ (white bars) and Sptlc2þ/þ (gray bars) mice fed normal chow (A) or a high-fat diet (B) was analyzed by LC-MS/MS. CeE: VEGF-induced activation of
Akt and eNOS in aortas of Sptlc2/þ and Sptlc2þ/þ mice fed normal chow or a high-fat diet was analyzed by immunoblotting. Representative immunoblots (C)
and densitometry analyses (D and E). F and G: AdVEGF-induced angiogenesis in the ears of high-fat-fed Sptlc2/þ and Sptlc2þ/þ mice. Representative images
(F) and quantitative analyses (G) are shown. Data are expressed as means  SD (A and B) or as means  SEM (CeE and G). nZ 3 mice per group. *P < 0.05,
***P < 0.001. Original magniﬁcation, 400.
Ceramide and Endothelial VEGF Resistancebioavailable NO is also diminished because of the produc-
tion of reactive oxygen species (ROS), given that FFA-
induced ROS generation has been demonstrated.32 At the
PA concentrations we used, there was no signiﬁcant in-
crease in EC ROS. Thus, although we believe that PA-
induced increases in endothelial ROS generation could
contribute to the endothelial dysfunction observed in
metabolic syndrome, we were able to segregate and to study
only those components of VEGF signaling abnormalities
that are not ROS-dependent.
In addition to abnormal endothelial function, angiogenic
and arteriogenic responses to ischemia are impaired in
metabolic syndrome and diabetes.33 The Matrigel angio-
genic cord formation assay incorporates multiple aspects of
VEGF-induced endothelial signaling required for angio-
genic responses in vivo. These include Akt-dependent eNOS
activation and NO release, as well as antiapoptosis and
ERK-mediated cell-cycle transition. VEGF-treated, PA-
exposed ECs are highly defective in their ability to formThe American Journal of Pathology - ajp.amjpathol.orgcords in Matrigel, consistent with an FFA-induced angio-
genic defect.
Extending our study to in vivo analyses, we found that 2.5-
week high-fat feeding led to signiﬁcant elevations in plasma
FFA and resulted in a marked impairment in VEGF-induced
aortic eNOS and Akt phosphorylation. In addition, we used
two in vivo models of VEGF-induced angiogenesis. Injected
replication-deﬁcient adenovirus encoding murine VEGF-A164
into the ear of white mice provides an in vivo assay with which
to assess a purely VEGF-driven angiogenic (and permeability)
response. The dramatic decrease in VEGF-induced capillary
neosynthesis in the mice fed a high-fat diet is consistent with
the observed in vitro and in vivo VEGF signaling defects. We
note, however, that the 2.5-week duration of high-fat feeding
in the present study is much shorter than the 12 to 14 weeks
common in metabolic studies in which marked weight gain
and frank diabetes occur.34
Our second in vivo angiogenesis model was one of severe
ischemia and hypoxia, in which VEGF-dependent responses1573
Mehra et alare critical in early phases of tissue recovery.26 Postischemic
microvessel angiogenic responses were signiﬁcantly
impaired in mice fed a high-fat diet. Collateral arterio-
genesis, documented by avb3 SPECT imaging in the prox-
imal hindlimb at a late time point, also was signiﬁcantly
impaired in mice fed a high-fat diet. This reﬂects a more
global defect in endothelial function and inadequate NO-
elaborating responses to additional growth factors impor-
tant in arteriogenesis. The combined imaging approaches
demonstrated a broad and sustained defect, over an
extended period, in complementary fashion.
Ceramide has been shown to mediate insulin resistance in
brown adipose tissue35 and to negatively regulate insulin
action in muscle by inhibiting Akt activity.36 With the
present study, we have demonstrated palmitate-induced
ceramide production in primary ECs, and aortic ceramide
generation in mice fed a high-fat diet, using LC-MS/MS to
document the increase in early-species ceramide metabo-
lites. The SPT inhibitor myriocin, an effective inhibitor of
the ﬁrst step in endogenous ceramide synthesis (ie, the
formation of 3-ketosphinganine from serine and palmitoyl-
CoA), largely prevented the inhibitory effect of PA on
VEGF-induced eNOS phosphorylation and cord formation.
Furthermore, using Sptlc2/þ mice, we demonstrated that
high-fat diet-induced impairment of VEGF signaling and
angiogenesis are largely dependent on de novo synthesis of
ceramide. One caveat is that SPT inhibition would cause
depletion of all sphingolipids. It is possible that, in addition
to ceramide, sphingomyelin could be playing an inhibitory
role. We found that the relatively speciﬁc sphingomyelin
synthase 2 inhibitor D609 had a marginal effect (much less
than myriocin) on PA-induced attenuation of VEGF-
stimulated eNOS phosphorylation (data not shown). How-
ever, it remains possible that other sphingolipids play some
role in this fatty acideinduced effect.
Because ceramide can activate PP2A, which in turn can
dephosphorylate Akt, eNOS, and ERK,36 we investigated
PP2A involvement in EC resistance to VEGF after short-
term exposure to PA. PP2AeeNOS association was
enhanced in PA-treated ECs, promoting dephosphorylation
and consequently reducing NO production. In a recent
report by Zhang et al,37 ceramide-induced association of
PP2A with eNOS and Akt was implicated in vascular
dysfunction and insulin resistance in obese mice, ﬁndings
similar to some of our observations on the ceram-
ideePP2AeeNOS axis; however, several factors and ﬁnd-
ings make the present study sufﬁciently distinct. First, the
much shorter duration of exposure of mice to a diet high in
saturated fat (3 weeks in the present study, compared with 3
months in the study of Zhang et al37) suggests that
ceramide-dependent PP2A-mediated VEGF resistance pre-
cedes obesity. Second, using much lower concentrations of
PA (100 mmol/L versus 500 mmol/L) and myriocin (100
nmol/L versus 10 mmol/L), which are more physiologically
relevant for PA and probably more speciﬁc for myriocin, we
demonstrated effects of PA and myriocin on VEGF-induced1574Akt and ERK phosphorylation, whereas Zhang et al37
indicated that de novo synthesized ceramide activates
PP2A without affecting Akt, ERK, or AMPK activation
after stimulation with insulin. Our present ﬁndings leave
open the possibility that signaling downstream of VEGFR2
is more sensitive to inhibition by ceramide-induced PP2A.
In preliminary experiments, we observed that this induced
signaling defect is not caused by all fatty acids; in particular,
the polyunsaturated fatty acid eicosapentaenoic acid had no
inhibitory effect (data not shown). This is consistent with
previous studies demonstrating augmented insulin-
stimulated NO production in cells pretreated with eicosa-
pentaenoic acid.38 A monosaturated prevalent fatty acid,
oleic acid, also did not attenuate VEGF-induced signaling in
our models (data not shown).
We have deﬁned a mechanism by which FFAs, such as
are elevated in metabolic syndrome, lead to endothelial
insensitivity to a prototypic angiogenic growth factor, a
defect that correlates with endothelial dysfunction. As
already noted, we chose relatively low concentrations of PA
and a model system in which we can segregate this
ceramide-activated PP2A effect. We recognize that many
other mechanisms could contribute to lipid-induced endo-
thelial abnormalities. Palmitate treatment can lead to the
reduction of key mitochondrial biogenesis regulators,
including PGC-1a and cytochrome c oxidase subunit IV.39
There are also potential links among ceramide, PKC, and
insulin resistance. Ceramide has been shown to disable the
Akt pleckstrin homology domain interaction with mem-
brane phosphatidylinositol-3,4,5-trisphosphate by activation
of PKC-z, which phosphorylates the Akt pleckstrin ho-
mology domain.40 Because of this potential ceram-
ideePKC-zeAkt link, we investigated the activation and
role of PKC-z in PA-induced inhibition of VEGF responses
in BAEC. At the PA concentrations we used, there was
minimal activation of PKC-z, and no reversal of the VEGF
signaling abnormalities on effective PKC-z inhibition using
a pseudosubstrate inhibitor (data not shown). Finally,
although we focused on VEGF responses and emphasized
vascular signaling initiated by prototypic angiogenic growth
factors, the role of abnormal insulin signaling may, in and of
itself, play a role in vascular pathology (as has been shown
by others41).
Thus, although there are likely many molecular contrib-
utors to vascular disease in dysmetabolic states, here we
have described an important and novel pathological
pathway induced by a direct PA effect on the endothelium.
Similar to insulin resistance in skeletal muscle and liver, this
is a form of VEGF resistance at the level of the endothelium
with diminished NO production and loss of growth factor-
mediated cell survival signals. This resistance suggests a
limited role for angiogenesis stimulation by simply
increasing growth factor delivery in ischemic conditions,
and likely explains the minimal success of VEGF trials in
vascular disease.42 The key role of ceramide in these VEGF
signaling abnormalities raises the possibility that safeajp.amjpathol.org - The American Journal of Pathology
Ceramide and Endothelial VEGF Resistancepharmacological inhibitors of endogenous ceramide syn-
thesis could promote maintenance of vascular homeostasis
in dysmetabolic states. Myriocin has been shown to atten-
uate atherosclerosis in murine models8 and, based on the
present study, it would be a useful agent in early endothelial
dysfunction studies. A potential application of these mo-
lecular studies is to direct preventive efforts toward main-
taining normal endothelial function in metabolic syndrome.
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